Search Results 431-440 of 16650 for alopecia

1. A Study to Evaluate Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer Patients with an ESR1 Mutation - Mayo Clinic

   Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry. ECOG performance score of ...

2. A Study to Evaluate the Effectiveness and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   0]) from acute non-hematologic toxicity (except ≤ Grade 2 neuropathy or alopecia), due to previous therapy, prior to screening. Hodgkin lymphoma (HL) with ...

3. Living With Cancer: The Emotions of Hair Loss - Mayo Clinic News Network

   Losing your hair to chemotherapy or radiation can have an emotional impact that you may not expect. ... Even after you've finished chemotherapy, some side effects ...

4. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

5. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma - Mayo Clinic

   due to prior treatments, excluding alopecia and Grade 2 neuropathy. Exclusion Criteria: The presence of any of the following will exclude a subject from ...

6. Oral Protocatechuic Acid (PCA) as a Prophylaxis Against C. Acnes Wound Colonization During Total Shoulder Arthroplasty. - Mayo Clinic

   About this study. The purpose of this study is to determine whether a preoperative oral course of the nutritional supplement PCA can result in the decrease ...

7. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   Patients who have not recovered from adverse events attributed to prior anti-cancer therapy (i.e. have residual toxicities > grade 1, except for alopecia, ...

8. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   ... alopecia;; Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is ...

9. A Study to Evaluate Belinostat and Guadecitabine or ASTX727 to Treat Unresectable and Metastatic Conventional Chondrosarcoma - Mayo Clinic

   ... alopecia and endocrinopathies from prior immunotherapy-based treatments that are well-controlled with hormone replacement. Patients who are receiving any ...

10. A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) - Mayo Clinic

    Ongoing toxicity of ≥ Grade 2 from prior anticancer therapy (except for alopecia, absolute neutrophil count [ANC] and platelets). For ANC and platelets ...